1. Yan R, Li J, Xiao Z, Fan X, Liu H, Xu Y, Sun R, Liu J, Yao J, An G, Shi Y, Ge Y*.DCLK1 suppresses tumor-specific cytotoxic T lymphocyte function through recruitment of MDSCs via the CXCL1-CXCR2 axis.Cellular and Molecular Gastroenterology and Hepatology.2023.15(2).463-485.SCI |
2. Liu Q, Liu H, Huang X, Fan X, Xiao Z, Yan R, Yao J, An G, Yang Ge* Miao J*, Liu J*.A targetable MYBL2-ATAD2 axis governs cell proliferation in ovarian cancer.CANCER GENE THERAPY.2023.30(1).192-208.SCI |
3. Ge Y, Liu H, Zhang Y, Liu J, Yan R, Xiao Z, Fan X, Huang X, An G*. Inhibition of DCLK1 kinase reverses epithelial-mesenchymal transition and restores T-cell activity in pancreatic ductal adenocarcinoma.Translational Oncology.2022.17.101317.SCI |
4. Yan R, Fan X, Xiao Z, Liu H, Huang X, Liu J, Zhang S, Yao J, An G*, Ge Y*.Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/β-Catenin activity and cancer stemness. Cancer Lett.2022.531.83-97.SCI |
5. Yang Ge, Huiyun Zhang, Nathaniel Weygant, Jiannan Yao.Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials.Front Pharmacol.2021.12.640099.SCI |
6. Yang Ge, Xiaona Fan, Huiyin Huang, Nathaniel Weygant, Guangyu An, Jiannan Yao.DCLK1-Short Splice Variant Promotes Esophageal Squamous Cell Carcinoma Progression Via the MAPK/ERK/MMP2 Pathway.Molecular Cancer Res.2021.19.1980-1991.SCI |
7. Hang Zheng, Heshu liu,Yang Ge*,Xin Wang*.Integrated single-cell and bulk RNA sequencing analysis identifies a cancer associated fibroblast-related signature for predicting prognosis and therapeutic responses in colorectal cancer.Cancer Cell International.2021.10.1186.SCI |
8. Li Tao, Huiyun Zhang, Guangyu An, Haoning Lan, Yaoqi Xu, Yang Ge*, Jiannan Yao*.Balancing the risk-benefit ratio of immune checkpoint inhibitor and anti-VEGF combination therapy in renal cell carcinoma: a systematic review and meta-analysis.Front Oncol..2021.11.739263.SCI |
9. Rui Yan,JianJian Li,Ying Zhou,Li Yao,Ruya Sun,Ying Xu,Yang Ge*,Guangyu An*.Inhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancer.Life Sciences.2020.1.241 (2020) 117150.SCI |
10. Heshu Liu,TaoWen,Ying Zhou,Xiaona Fan,Tan Du,Tianbo Gao,Lina Li,Jian Liu,Lei Yang,Jiannan Yao,Yang Ge*,Guangyu An*.DCLK1 Plays a Metastatic-Promoting Role in Human Breast Cancer Cells.BioMed Research International.2019.5.Volume 2019, Article ID 1061979, 8 pages.SCI |
11. Yang Ge#*,C.Benedikt Westphalen,Wen Wee Ma,Kenneth J.Vega,Nathaniel Weygant*.Implications for Tumor Microenvironment and EpithelialCrosstalk in the Management of Gastrointestinal Cancers.Journal of Oncology.2019.10.Volume 2019, Article ID 4835318, 11 pages.SCI |
12. Ge Y#, Weygant N#, Qu D, May R, Berry WL, Yao J, Chandrakesan P, Zheng W Zhao L, Zhao KL, Drake M, Vega KJ,Bronze MS, Tomasek JJ, An G*, Houchen CW*.Alternative splice variants of DCLK1 mark cancer stem cells,promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer .INTERNATIONAL JOURNAL OF CANCER.2018.143(5).1162-1175.SCI |
13. Weygant N#, Ge Y#, Qu D, Kaddis JS, Berry WL, May R, Chandrakesan P, Bannerman-Menson E, Vega KJ, Tomasek JJ, Bronze MS, An G*, Houchen CW*.Survival of Patients with Gastrointestinal Cancers Can Be Predicted by a Surrogate microRNA Signature for Cancer Stem–like Cells Marked by DCLK1 Kinase .Cancer Research.2016.76(14).4090-4099.SCI |